FDA approves Ironwood's gout combo

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone.

The company expects to launch the fixed-dose combination early next quarter, and said it will elaborate on the specific price of the drug closer to launch. Ironwood Chief Commercial Officer Thomas McCourt told BioCentury the pricing will be similar to that of Zurampic lesinurad, one of Duzallo’s components...